Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: ewolf who wrote (456)	10/18/2005 3:32:50 PM
From: tuck	Read Replies (1) \| Respond to of 590

I think the price action on AMGN is muddied by many other things, and inferring anything about panitumumab from it is hopeless. The logical play would be to sell the bejeesus of ABGX, which is happening. But it would be stealthier to buy IMCL. Until the last few days, the IMCL indicator was flat, making folks wonder if there really was a leak, as opposed to mere nervousness. The action the last few days, and today in particular, however, makes the leak theory look a bit better: finance.yahoo.com Nigel once floated the idea that ABGX might be a pretty interesting long if pan failed. Given the apparent good performance of the AMGN/ABGX osteoporosis drug -- AMG-162, if memory serves me correctly -- among other programs flowing from the ABGX pipe, that's an idea to keep in mind. Cheers, Tuck